Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:21 AM
Ignite Modification Date:
2025-12-25 @ 1:21 AM
NCT ID:
NCT06040593
Eligibility Criteria:
Inclusion Criteria:
* Newly diagnosed HR+ and HER2-low/negative breast cancer diagnosed between January 1, 2010 and December 31, 2022 (Aged ≥18 years at the time of diagnosis)
* Stage I-IIIB at the time of diagnosis
* Received neoadjuvant chemotherapy and/or endocrine therapy and/or IO therapy
* Received curative intent surgery (mastectomy after neoadjuvant chemotherapy, endocrine, or IO therapy)
Exclusion Criteria:
* Patients who received HER2-targeted therapies including
* Trastuzumab
* Pertuzumab
* Ado-trastuzumab emtansine
* Neratinib
* Tucatinib
* Lapatinib
* Fam-trastuzumab deruxtecan-nxki
* Margetuximab
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06040593
Study Brief:
Protocol Section:
NCT06040593